W.G. Shaheen & Associates DBA Whitney & Co Buys New Stake in Bristol Myers Squibb Company $BMY

W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 13,139 shares of the biopharmaceutical company’s stock, valued at approximately $709,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. grew its position in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the last quarter. KERR FINANCIAL PLANNING Corp purchased a new position in Bristol Myers Squibb during the 3rd quarter worth $35,000. Finally, JPL Wealth Management LLC purchased a new position in Bristol Myers Squibb during the 3rd quarter worth $36,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q1 results beat expectations: GAAP/adjusted EPS of $1.58 vs. $1.46 consensus and revenue of $11.49B vs. $10.85B — evidence of continued demand for newer therapies. Article Title
• Positive Sentiment: Sales drivers called out: growth in blood thinner Eliquis and newer cancer medicines powered the revenue beat, supporting near‑term cash flow and margins. Article Title
• Positive Sentiment: Precision‑oncology collaboration expanded — Foundation Medicine is developing a companion diagnostic (FoundationOne CDx) for MTAP deletion to help match patients to Bristol Myers’ targeted programs, which could enhance future oncology uptake. Article Title
• Neutral Sentiment: Analyst moves were tiny: Erste trimmed FY‑2026 EPS a penny (6.29 → 6.28) while nudging FY‑2027 estimates slightly higher; consensus remains near management’s EPS midpoint. (no link)
• Neutral Sentiment: Pre‑earnings coverage and valuations were already highlighting cost‑cuts and portfolio strength, so some of today’s price action reflects reassessment rather than new surprises. Article Title
• Negative Sentiment: FY‑2026 guidance was mixed: management set EPS at $6.05–$6.35 (roughly in line with consensus) but revenue guidance of $46.0B–$47.5B has a midpoint (~$46.75B) slightly below the ~$47.1B consensus — investors often react negatively when revenue midpoints undershoot expectations. Article Title

Wall Street Analysts Forecast Growth

BMY has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. HSBC raised their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Barclays initiated coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $57.64 on Thursday. The company has a market cap of $117.69 billion, a PE ratio of 16.71, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company has a 50-day simple moving average of $59.55 and a 200-day simple moving average of $54.43.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.85 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.28 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.